GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » ROE % Adjusted to Book Value

VRCA (Verrica Pharmaceuticals) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals ROE % Adjusted to Book Value?

Verrica Pharmaceuticals's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Verrica Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Verrica Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.


Verrica Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Verrica Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals ROE % Adjusted to Book Value Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -5.80 -9.82 -13.84 -23.91 -14.26

Verrica Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.61 -20.19 -4.65 - -

Competitive Comparison of Verrica Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Verrica Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verrica Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's ROE % Adjusted to Book Value falls into.



Verrica Pharmaceuticals ROE % Adjusted to Book Value Calculation

Verrica Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-224.08% / 15.71
=-14.26%

Verrica Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verrica Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Verrica Pharmaceuticals Business Description

Traded in Other Exchanges
Address
44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Executives
Ted White director, officer: President and CEO C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Christopher G. Hayes officer: General Counsel C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Joe Bonaccorso officer: Chief Commercial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Gary Goldenberg director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson 10 percent owner C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk officer: Chief Operating Officer 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Verrica Pharmaceuticals Headlines

From GuruFocus

Verrica Announces Proposed Public Offering

By Marketwired 11-20-2024